EcoDrugPlus

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSMZEG00005006319
Gene Symbol: NOD2
3 Cross references
166 Possible Orthologues:

Opioid Receptor Delta 1

Ensembl ID : ENSMZEG00005015794
Gene Symbol: OPRD1
3 Cross references
179 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSMZEG00005001899
Gene Symbol: OPRK1
3 Cross references
197 Possible Orthologues:

Opioid Receptor, Kappa 1

Ensembl ID : ENSMZEG00005020023
Gene Symbol: OPRK1
1 Cross references
196 Possible Orthologues:

Opioid Related Nociceptin Receptor 1

Ensembl ID : ENSMZEG00005026803
Gene Symbol: OPRL1
3 Cross references
189 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSMZEG00005010574
Gene Symbol: OXTR
3 Cross references
191 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSMZEG00005015467
Gene Symbol: OXTR
1 Cross references
183 Possible Orthologues:

Parathyroid Hormone/parathyroid Hormone-Related Peptide Receptor

Ensembl ID : ENSMZEG00005024968
Gene Symbol: LOC101476084
3 Cross references
196 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Alpha

Ensembl ID : ENSMZEG00005012172
Gene Symbol: PPARA
3 Cross references
383 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Delta

Ensembl ID : ENSMZEG00005001947
Gene Symbol: PPARD
3 Cross references
392 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSMZEG00005013881
Gene Symbol: PPARG
4 Cross references
386 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Alpha

Ensembl ID : ENSMZEG00005010181
Gene Symbol: LOC101469131
3 Cross references
396 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).